Octagon Capital Advisors LP Taysha Gene Therapies, Inc. Transaction History
Octagon Capital Advisors LP
- $449 Million
- Q4 2024
A detailed history of Octagon Capital Advisors LP transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Octagon Capital Advisors LP holds 10,450,000 shares of TSHA stock, worth $16.8 Million. This represents 4.03% of its overall portfolio holdings.
Number of Shares
10,450,000
Previous 4,572,222
128.55%
Holding current value
$16.8 Million
Previous $9.19 Million
96.71%
% of portfolio
4.03%
Previous 2.22%
Shares
5 transactions
Others Institutions Holding TSHA
# of Institutions
130Shares Held
151MCall Options Held
48KPut Options Held
7.8K-
Avoro Capital Advisors LLC New York, NY20MShares$32.2 Million0.5% of portfolio
-
Morgan Stanley New York, NY17.6MShares$28.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$18.9 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$17.5 Million0.3% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.91MShares$14.3 Million0.0% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $77.9M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...